Clinical Trial Update: Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Auriclosene for bacterial conjunctivitis has completed, reporting on its efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Conjunctivitis

Drugs mentioned

• Auriclosene (auriclosene)

Snippet

Sponsor: NovaBay Pharmaceuticals, Inc. | Conditions: Bacterial Conjunctivitis | Phase 2 | Status: COMPLETED